Begin typing your search above and press return to search.
Schools breeding hatred
access_time 14 Sep 2023 10:37 AM GMT
access_time 16 Aug 2023 5:46 AM GMT
May that spark not be extinguished
access_time 2 Dec 2023 8:55 AM GMT
A Constitution always in the making
access_time 27 Nov 2023 11:43 AM GMT
Debunking myth of Israel’s existence
access_time 23 Oct 2023 7:01 AM GMT
Homechevron_rightMiddle Eastchevron_rightBahrain approves...

Bahrain approves Oxford-AstraZeneca vaccine after Sinopharma and Pfizer

Bahrain approves Oxford-AstraZeneca vaccine after Sinopharma and Pfizer

Source: BNA

The National Health Regulatory Authority (NHRA) of Bahrain approved Covishield, the Oxford-AstraZeneca COVID-19 vaccine, for emergency use, state news agency BNA reported on Monday. Covishield is manufactured at the Serum Institute of India (SII), the world's largest vaccine manufacturer.

The Oxford-AstraZeneca vaccine is the third to be approved by Bahrain for emergency use following SinoPharma and Pfizer-BioNTech. The Gulf state has directed the authorities to administer vaccines for people at the highest risks of developing complications from the coronavirus.

NHRA Chief Executive Officer Dr Mariam Adhbi Al-Jalahma informed that the vaccine was sanctioned after several procedures for monitoring its quality, safety and effectiveness. The vaccine is administered as two jabs; the second jab is administered 28 days after the first. According to BNA, AstraZeneca shows its effectiveness after the second dose reaches 70.42 per cent.

The Bahrain Health Ministry had earlier announced the rescheduling of the first doses of Pfizer vaccine administration as the pharmaceutical company's manufacturing unit expanded urgently. However, all appointments for the second dose of the Pfizer-BioNTech vaccine will remain unaffected and go ahead as scheduled.

Show Full Article
TAGS:COVID19Covid UpdatesVaccination
Next Story